Molecular hierarchy of heparin-binding EGF-like growth factor-regulated angiogenesis in triple-negative breast cancer

Fusanori Yotsumoto, Eriko Tokunaga, Eiji Oki, Yoshihiko Maehara, Hiromi Yamada, Kyoko Nakajima, Sung Ouk Nam, Kohei Miyata, Midori Koyanagi, Keiko Doi, Senji Shirasawa, Masahide Kuroki, Shingo Miyamoto

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Heparin-binding EGF-like growth factor (HB-EGF) is one of several proangiogenic factors and represents a possible therapeutic target for patients with triple-negative breast cancer (TNBC). However, the role of HBEGF in promoting tumor aggressiveness in TNBC remains unclear. To investigate specific genes and pathways involved in TNBC tumorigenesis, we profiled gene expression changes in two TNBC cell lines under two-dimensional culture (2DC) and three-dimensional culture (3DC) and in a tumor xenograft model. We identified simultaneous upregulation of HB-EGF, VEGFA, and angiopoietin-like 4 (ANGPTL4) in 3DC and tumor xenografts, compared with 2DC. We show that HB-EGF regulates the expression of VEGFA or ANGPTL4 via transcriptional regulation of hypoxia-inducible factor-1α and NF-κB. Furthermore, suppression of VEGFA or ANGPTL4 expression enhanced HB-EGF expression, highlighting a unique regulatory loop underlying this angiogenesis network. Targeted knockdown of HB-EGF significantly suppressed tumor formation in a TNBC xenograft model, compared with individual knockdown of either VEGFA or ANGPTL4, by reducing the expression of both VEGFA and ANGPTL4. In patients with TNBC, VEGFA or ANGPTL4 expression was also significantly correlated with HB-EGF expression. Low concentrations of exogenously added HB-EGF strongly activated the proliferation of endothelial cells, tube formation, and vascular permeability in blood vessels, in a similar fashion to high doses of VEGFA and ANGPTL4. Taken together, these results suggest that HB-EGF plays a pivotal role in the acquisition of tumor aggressiveness in TNBC by orchestrating a molecular hierarchy regulating tumor angiogenesis.

Original languageEnglish
Pages (from-to)506-517
Number of pages12
JournalMolecular Cancer Research
Volume11
Issue number5
DOIs
Publication statusPublished - May 1 2013

Fingerprint

Triple Negative Breast Neoplasms
Heterografts
Neoplasms
Hypoxia-Inducible Factor 1
Heparin-binding EGF-like Growth Factor
Capillary Permeability
angiopoietin 4
Blood Vessels
Carcinogenesis
Up-Regulation
Endothelial Cells
Gene Expression
Cell Line

All Science Journal Classification (ASJC) codes

  • Molecular Biology
  • Oncology
  • Cancer Research

Cite this

Molecular hierarchy of heparin-binding EGF-like growth factor-regulated angiogenesis in triple-negative breast cancer. / Yotsumoto, Fusanori; Tokunaga, Eriko; Oki, Eiji; Maehara, Yoshihiko; Yamada, Hiromi; Nakajima, Kyoko; Nam, Sung Ouk; Miyata, Kohei; Koyanagi, Midori; Doi, Keiko; Shirasawa, Senji; Kuroki, Masahide; Miyamoto, Shingo.

In: Molecular Cancer Research, Vol. 11, No. 5, 01.05.2013, p. 506-517.

Research output: Contribution to journalArticle

Yotsumoto, F, Tokunaga, E, Oki, E, Maehara, Y, Yamada, H, Nakajima, K, Nam, SO, Miyata, K, Koyanagi, M, Doi, K, Shirasawa, S, Kuroki, M & Miyamoto, S 2013, 'Molecular hierarchy of heparin-binding EGF-like growth factor-regulated angiogenesis in triple-negative breast cancer', Molecular Cancer Research, vol. 11, no. 5, pp. 506-517. https://doi.org/10.1158/1541-7786.MCR-12-0428
Yotsumoto, Fusanori ; Tokunaga, Eriko ; Oki, Eiji ; Maehara, Yoshihiko ; Yamada, Hiromi ; Nakajima, Kyoko ; Nam, Sung Ouk ; Miyata, Kohei ; Koyanagi, Midori ; Doi, Keiko ; Shirasawa, Senji ; Kuroki, Masahide ; Miyamoto, Shingo. / Molecular hierarchy of heparin-binding EGF-like growth factor-regulated angiogenesis in triple-negative breast cancer. In: Molecular Cancer Research. 2013 ; Vol. 11, No. 5. pp. 506-517.
@article{ed60849a80674489a2b4a572ff87612a,
title = "Molecular hierarchy of heparin-binding EGF-like growth factor-regulated angiogenesis in triple-negative breast cancer",
abstract = "Heparin-binding EGF-like growth factor (HB-EGF) is one of several proangiogenic factors and represents a possible therapeutic target for patients with triple-negative breast cancer (TNBC). However, the role of HBEGF in promoting tumor aggressiveness in TNBC remains unclear. To investigate specific genes and pathways involved in TNBC tumorigenesis, we profiled gene expression changes in two TNBC cell lines under two-dimensional culture (2DC) and three-dimensional culture (3DC) and in a tumor xenograft model. We identified simultaneous upregulation of HB-EGF, VEGFA, and angiopoietin-like 4 (ANGPTL4) in 3DC and tumor xenografts, compared with 2DC. We show that HB-EGF regulates the expression of VEGFA or ANGPTL4 via transcriptional regulation of hypoxia-inducible factor-1α and NF-κB. Furthermore, suppression of VEGFA or ANGPTL4 expression enhanced HB-EGF expression, highlighting a unique regulatory loop underlying this angiogenesis network. Targeted knockdown of HB-EGF significantly suppressed tumor formation in a TNBC xenograft model, compared with individual knockdown of either VEGFA or ANGPTL4, by reducing the expression of both VEGFA and ANGPTL4. In patients with TNBC, VEGFA or ANGPTL4 expression was also significantly correlated with HB-EGF expression. Low concentrations of exogenously added HB-EGF strongly activated the proliferation of endothelial cells, tube formation, and vascular permeability in blood vessels, in a similar fashion to high doses of VEGFA and ANGPTL4. Taken together, these results suggest that HB-EGF plays a pivotal role in the acquisition of tumor aggressiveness in TNBC by orchestrating a molecular hierarchy regulating tumor angiogenesis.",
author = "Fusanori Yotsumoto and Eriko Tokunaga and Eiji Oki and Yoshihiko Maehara and Hiromi Yamada and Kyoko Nakajima and Nam, {Sung Ouk} and Kohei Miyata and Midori Koyanagi and Keiko Doi and Senji Shirasawa and Masahide Kuroki and Shingo Miyamoto",
year = "2013",
month = "5",
day = "1",
doi = "10.1158/1541-7786.MCR-12-0428",
language = "English",
volume = "11",
pages = "506--517",
journal = "Molecular Cancer Research",
issn = "1541-7786",
publisher = "American Association for Cancer Research Inc.",
number = "5",

}

TY - JOUR

T1 - Molecular hierarchy of heparin-binding EGF-like growth factor-regulated angiogenesis in triple-negative breast cancer

AU - Yotsumoto, Fusanori

AU - Tokunaga, Eriko

AU - Oki, Eiji

AU - Maehara, Yoshihiko

AU - Yamada, Hiromi

AU - Nakajima, Kyoko

AU - Nam, Sung Ouk

AU - Miyata, Kohei

AU - Koyanagi, Midori

AU - Doi, Keiko

AU - Shirasawa, Senji

AU - Kuroki, Masahide

AU - Miyamoto, Shingo

PY - 2013/5/1

Y1 - 2013/5/1

N2 - Heparin-binding EGF-like growth factor (HB-EGF) is one of several proangiogenic factors and represents a possible therapeutic target for patients with triple-negative breast cancer (TNBC). However, the role of HBEGF in promoting tumor aggressiveness in TNBC remains unclear. To investigate specific genes and pathways involved in TNBC tumorigenesis, we profiled gene expression changes in two TNBC cell lines under two-dimensional culture (2DC) and three-dimensional culture (3DC) and in a tumor xenograft model. We identified simultaneous upregulation of HB-EGF, VEGFA, and angiopoietin-like 4 (ANGPTL4) in 3DC and tumor xenografts, compared with 2DC. We show that HB-EGF regulates the expression of VEGFA or ANGPTL4 via transcriptional regulation of hypoxia-inducible factor-1α and NF-κB. Furthermore, suppression of VEGFA or ANGPTL4 expression enhanced HB-EGF expression, highlighting a unique regulatory loop underlying this angiogenesis network. Targeted knockdown of HB-EGF significantly suppressed tumor formation in a TNBC xenograft model, compared with individual knockdown of either VEGFA or ANGPTL4, by reducing the expression of both VEGFA and ANGPTL4. In patients with TNBC, VEGFA or ANGPTL4 expression was also significantly correlated with HB-EGF expression. Low concentrations of exogenously added HB-EGF strongly activated the proliferation of endothelial cells, tube formation, and vascular permeability in blood vessels, in a similar fashion to high doses of VEGFA and ANGPTL4. Taken together, these results suggest that HB-EGF plays a pivotal role in the acquisition of tumor aggressiveness in TNBC by orchestrating a molecular hierarchy regulating tumor angiogenesis.

AB - Heparin-binding EGF-like growth factor (HB-EGF) is one of several proangiogenic factors and represents a possible therapeutic target for patients with triple-negative breast cancer (TNBC). However, the role of HBEGF in promoting tumor aggressiveness in TNBC remains unclear. To investigate specific genes and pathways involved in TNBC tumorigenesis, we profiled gene expression changes in two TNBC cell lines under two-dimensional culture (2DC) and three-dimensional culture (3DC) and in a tumor xenograft model. We identified simultaneous upregulation of HB-EGF, VEGFA, and angiopoietin-like 4 (ANGPTL4) in 3DC and tumor xenografts, compared with 2DC. We show that HB-EGF regulates the expression of VEGFA or ANGPTL4 via transcriptional regulation of hypoxia-inducible factor-1α and NF-κB. Furthermore, suppression of VEGFA or ANGPTL4 expression enhanced HB-EGF expression, highlighting a unique regulatory loop underlying this angiogenesis network. Targeted knockdown of HB-EGF significantly suppressed tumor formation in a TNBC xenograft model, compared with individual knockdown of either VEGFA or ANGPTL4, by reducing the expression of both VEGFA and ANGPTL4. In patients with TNBC, VEGFA or ANGPTL4 expression was also significantly correlated with HB-EGF expression. Low concentrations of exogenously added HB-EGF strongly activated the proliferation of endothelial cells, tube formation, and vascular permeability in blood vessels, in a similar fashion to high doses of VEGFA and ANGPTL4. Taken together, these results suggest that HB-EGF plays a pivotal role in the acquisition of tumor aggressiveness in TNBC by orchestrating a molecular hierarchy regulating tumor angiogenesis.

UR - http://www.scopus.com/inward/record.url?scp=84877891176&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877891176&partnerID=8YFLogxK

U2 - 10.1158/1541-7786.MCR-12-0428

DO - 10.1158/1541-7786.MCR-12-0428

M3 - Article

C2 - 23443317

AN - SCOPUS:84877891176

VL - 11

SP - 506

EP - 517

JO - Molecular Cancer Research

JF - Molecular Cancer Research

SN - 1541-7786

IS - 5

ER -